Alessandro Bosi

2 months ago | jamanetwork.com | Tao Huang |Alessandro Bosi |Anne-Laure Faucon |Morgan E. Grams

Error in Figure and Results GLP-1RA vs DPP-4i Use and Hyperkalemia and RAS Blockade Discontinuation Tao Huang, MSc; Alessandro Bosi, MSc; Anne-Laure Faucon, MD, PhD; Morgan E. Grams, MD, PhD; Arvid Sjölander, PhD; Edouard L.

Dec 18, 2024 | ejves.com | Shigeru Tanaka |Alessandro Bosi |Edouard L. Fu |Kunitoshi Iseki |Takanari Kitazono |Rebecka Hultgren | +2 more

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes Full length articleArticles in PressOpen access aDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden bDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan...

Aug 12, 2024 | jamanetwork.com | Tao Huang |Alessandro Bosi |Morgan E. Grams

Key PointsQuestion  Is the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) vs dipeptidyl peptidase-4 inhibitors (DPP-4is) associated with different rates of hyperkalemia or prolonged renin-angiotensin system (RAS) inhibitor use in people with type 2 diabetes (T2D)? Findings  In this cohort study of 33 280 patients with T2D, the use of GLP-1RAs was associated with a lower rate of hyperkalemia and prolonged RAS inhibitor use compared with the use of DPP-4is.